Dyslipidemia

>

Latest News

Patient Factors Influence Semaglutide Initiation After Obesity Diagnosis | Image Credit: Boston University
Patient Factors Influence Semaglutide Initiation After Obesity Diagnosis

January 21st 2025

Approximately 2.0% of commercially insured individuals with obesity, but not diabetes, initiated semaglutide within 6 months of diagnosis.

HDL Antioxidant Function Diminished in Patients with HFpEF, Study Finds | Image Credit: Fotolia
HDL Antioxidant Function Diminished in Patients with HFpEF, Study Finds

January 21st 2025

FDA Accepts Plozasiran NDA for Familial Chylomicronemia Syndrome | Image Credit: US Food and Drug Administration
FDA Accepts Plozasiran NDA for Familial Chylomicronemia Syndrome

January 20th 2025

Semaglutide 7.2 mg Exhibits 20.7% Weight Loss in Phase 3b STEP UP Trial | Image Credit: Novo Nordisk
Semaglutide 7.2 mg Displays 20.7% Weight Loss in Phase 3b STEP UP Trial

January 17th 2025

Genetic Determinants of LDL-C Inversely Linked to Type 2 Diabetes Risk | Image Credit: Massachusetts General Hospital
Genetic Determinants of LDL-C Inversely Linked to Type 2 Diabetes Risk

January 15th 2025

<1
...
3536373839
© 2025 MJH Life Sciences

All rights reserved.